Startseite>>Signaling Pathways>> GPCR/G protein>> Leukotriene Receptor>>LTD4 antagonist 1

LTD4 antagonist 1

Katalog-Nr.GC31944

LTD4-Antagonist 1 ist ein potenter, oral aktiver Antagonist von Leukotrien D4 (LTD4) mit einem Ki von 0,57 nM.

Products are for research use only. Not for human use. We do not sell to patients.

LTD4 antagonist 1 Chemische Struktur

Cas No.: 136564-67-5

Größe Preis Lagerbestand Menge
1mg
1.176,00 $
Auf Lager
5mg
2.354,00 $
Auf Lager
10mg
3.998,00 $
Auf Lager
20mg
7.060,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

LTD4 antagonist 1 is a potent, orally active antagonist of leukotriene D4 (LTD4) with a Ki of 0.57 nM.

LTD4 antagonist 1 (Compound 38b) exhibits a Ki of 0.57 nM for displacement of [3H]LTD4 on guinea pig lung membranes, a pKB of 9.93±0.14 versus LTE4 on guinea pig trachea[1].

LTD4 antagonist 1 (Compound 38b) exhibits a po ED50/iv ED50 of 1.44 and 0.036 μmol/kg in LTD4-induced bronchoconstriction in guinea pigs[1].

[1]. Robert T. Jacobs, et al. Synthesis, Structure-Activity Relationships, and Pharmacological Evaluation of a Series of Fluorinated 3-Benzyl-5-Indolecarboxamides: Identification of 4-[[5-[((2R)-2-Methyl-4,4,4-trifluorobutyl)carbamoyl]-1-methylindol-3-yl]methyl]-3methoxy-N-[(2-methylphenyl)sulfonyl]benzamide, a Potent, Orally Active Antagonist of Leukotrienes D4 and E4. Journal of Medicinal Chemistry (1994), 37(9), 1282-97.

Bewertungen

Review for LTD4 antagonist 1

Average Rating: 5 ★★★★★ (Based on Reviews and 36 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for LTD4 antagonist 1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.